Building Muscle, But Not Bone Density? Your Genes May Be Holding You Back.

Your VDR gene produces a receptor protein that sits on the surface of intestinal cells and bone cells. When vitamin D binds to it, it opens the door for calcium absorption and signals your bones to mineralize. Without functional VDR, calcium passes right through you; your bones can’t access the raw material they need to get stronger.

The VDR gene has multiple variant sites (BsmI, FokI, TaqI). Roughly 30-50% of the population carries at least one variant that reduces VDR function. This doesn’t mean you can’t absorb calcium, but it means your absorption rate is 30-40% lower than someone with the optimal variant. You’re absorbing less calcium from the same amount of food and supplementation.

If you carry a VDR variant, resistance training stimulus reaches your bones, but the calcium signaling is dampened. You’re building the stimulus, but not building the mineral density your bones need to handle future load. Over time, your bones become stronger in structure but more fragile in density. This is why some lifters have good muscle but poor bone scan results.

Collagen type I is the protein scaffold that gives bone its tensile strength. It’s the framework that calcium mineralization fills in. If your collagen is weak or cross-linked poorly, your bones become brittle even if they’re mineralized. COL1A1 is the gene that produces this critical structural protein.

The Sp1 site variant (rs1800012) in COL1A1, present in roughly 15-20% of people, reduces collagen cross-linking efficiency. This means your bones lay down mineral at a normal rate, but the underlying matrix is structurally weaker. Your bone density numbers might look fine on paper, but your actual fracture resistance is compromised. This variant is particularly important in the context of resistance training because heavy loading stresses the collagen scaffold.

If you carry this variant, your bones can absorb all the calcium they need, but they’re not building the tensile strength that prevents fractures. You can have adequate bone density and still break a bone from a fall that wouldn’t fracture someone with optimal COL1A1. Resistance training helps (mechanical loading stimulates collagen remodeling), but without targeted support, the response is suboptimal.

Estrogen is one of the most potent bone-protective hormones in the body. It works by binding to estrogen receptors (ESR1) on the surface of bone cells. When estrogen connects, it suppresses osteoclasts (bone-resorbing cells) and supports osteoblasts (bone-building cells). Without adequate ESR1 function, estrogen’s protective signal doesn’t get through, even if your hormone levels are normal.

ESR1 variants (PvuII and XbaI polymorphisms) are carried by roughly 40% of the population and reduce receptor sensitivity to circulating estrogen. This means your bones receive a weaker protective signal from estrogen, even if your E2 levels are adequate. For postmenopausal women, this accelerates bone loss. For men, it reduces the baseline bone-protective effect of lower testosterone-derived estrogen.

During resistance training, estrogen amplifies the signal that tells your bones to build. If your ESR1 receptor is less sensitive, resistance training still works, but the hormonal amplification is muted. This is why some women have excellent training consistency and still experience bone loss after menopause; their ESR1 variants didn’t suddenly matter until estrogen dropped. The effect is strongest in women, but men with ESR1 variants also see reduced bone-building response to training.

LRP5 is a co-receptor in the Wnt signaling pathway, one of the master regulators of bone formation. When Wnt signaling is active, it tells osteoblasts (bone-building cells) to work harder and proliferate. When it’s suppressed, bone formation slows and resorption dominates. LRP5 variants reduce the efficiency of this pathway, meaning your bones respond more sluggishly to the signal that says “build more bone.”

LRP5 variants are common in the population and reduce osteoblast activity and peak bone mass potential. This means your bones have a lower genetic ceiling for how dense and strong they can become, even with optimal training and nutrition. You’re not starting from the same baseline as someone with optimal LRP5. You’re working with a system that was genetically programmed for lower bone production.

In the context of resistance training, LRP5 variants mean you’ll build bone more slowly and reach a lower peak bone mass, even with consistent, heavy loading. This doesn’t mean training isn’t worth it. It means you need to train longer, harder, and more consistently to reach the same endpoint as someone with optimal LRP5. It’s the difference between reaching 90% of potential bone density in two years versus five years.

MTHFR is the enzyme that processes folate into the form your cells can use for methylation reactions and one-carbon metabolism. When MTHFR is functioning optimally, homocysteine stays low. Homocysteine is a bone-damaging amino acid byproduct; high homocysteine directly interferes with collagen cross-linking, making your bone matrix structurally weaker even if it’s well-mineralized.

The MTHFR C677T variant, present in roughly 40% of people with European ancestry, reduces enzyme activity by 35-40%. This means homocysteine tends to rise, even if your B12 and folate intake is adequate. Elevated homocysteine doesn’t just damage bone quality; it also impairs the cellular signaling that tells osteoblasts to build. You’re working against two problems: weaker collagen scaffolding and reduced bone-building signals.

During resistance training, your bones are receiving strong mechanical signals to build, but elevated homocysteine is simultaneously weakening the collagen matrix they’re building from. You get the stimulus, but the material quality is compromised. This is particularly important because MTHFR variants are common and often overlooked in bone health discussions. You can do everything right with training and calcium, but if homocysteine is elevated from an MTHFR variant, your fracture risk remains high.

Bone is constantly being broken down and rebuilt. RANKL is a signaling molecule that activates osteoclasts (the cells that break bone down). OPG (osteoprotegerin) is the brake that stops RANKL. The balance between RANKL and OPG determines whether your skeleton is in a bone-building state or a bone-losing state. Variants in RANKL or related signaling tilts this balance toward resorption.

RANKL variants are common and shift the RANKL/OPG ratio toward increased bone resorption. This means your skeleton is biased toward breaking down bone faster than building it, even when you’re providing stimulus (like resistance training) to build. You’re pushing one way, but your genetics are pulling the other way. The remodeling cycle is more aggressive in the resorption phase and less robust in the formation phase.

For someone with RANKL variants, resistance training still helps, but the benefit is smaller and slower. It’s like trying to fill a bathtub while the drain is wide open. You’re adding water (bone formation), but it’s draining faster than normal (resorption). You need to close the drain (reduce RANKL signaling) while simultaneously increasing the flow (training stimulus).